3,033 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Bought by Wolverine Trading LLC

Wolverine Trading LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,033 shares of the company’s stock, valued at approximately $343,000.

A number of other hedge funds have also recently bought and sold shares of the company. Riverview Trust Co bought a new position in shares of Vaxcyte during the third quarter valued at about $27,000. Fifth Third Bancorp bought a new position in shares of Vaxcyte during the 2nd quarter worth approximately $35,000. Blue Trust Inc. boosted its stake in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares during the last quarter. Quest Partners LLC bought a new position in shares of Vaxcyte in the second quarter valued at approximately $70,000. Finally, Meeder Asset Management Inc. increased its position in shares of Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after acquiring an additional 635 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Down 0.2 %

PCVX stock opened at $87.72 on Friday. The stock has a 50-day simple moving average of $101.11 and a two-hundred day simple moving average of $91.68. Vaxcyte, Inc. has a twelve month low of $53.83 and a twelve month high of $121.06. The firm has a market capitalization of $10.93 billion, a PE ratio of -19.07 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter in the previous year, the firm posted ($0.91) EPS. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PCVX has been the topic of several research analyst reports. Bank of America boosted their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Needham & Company LLC restated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Jefferies Financial Group lifted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. BTIG Research boosted their target price on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Mizuho increased their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $147.50.

Insider Transactions at Vaxcyte

In related news, CEO Grant Pickering sold 2,366 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $92.25, for a total transaction of $218,263.50. Following the completion of the transaction, the chief executive officer now directly owns 136,215 shares in the company, valued at $12,565,833.75. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mikhail Eydelman sold 5,000 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $109.27, for a total value of $546,350.00. Following the completion of the sale, the senior vice president now directly owns 28,623 shares in the company, valued at approximately $3,127,635.21. The trade was a 14.87 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 117,830 shares of company stock valued at $12,600,310. 3.10% of the stock is currently owned by company insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.